Physician profile
Marc A Scheer
NPI 1013194414
$9,002.21
in general payments reported to CMS, 2019-2025
30 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $267 · 2021: $441 · 2022: $1,052 · 2023: $1,332 · 2024: $2,883 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,421 · Education: $26.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,420.76 |
| Education | $26.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,636.73 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $1,181.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,071.32 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $904.54 | 2019-2025 | Stelara, Tremfya, Simponi |
| Aimmune Therapeutics, INC. | $855.53 | 2024 | |
| Genzyme Corporation | $475.94 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.25 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $357.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $346.76 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $240.48 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $225.93 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $207.92 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $204.65 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $155.81 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $152.80 | 2019-2024 | Linzess |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.98 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $79.44 | 2024-2025 | Voquezna |
| Ucb, INC. | $64.51 | 2019-2024 | Cimzia |
| Amgen INC. | $55.77 | 2021-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $55.53 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $41.61 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $35.76 | 2022-2024 | Injectafer |
| Celltrion USA INC. | $33.24 | 2024-2025 | Vegzelma, Zymfentra |
| Covidien Lp | $23.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Alfasigma USA, INC. | $17.87 | 2020 | |
| Welch Allyn | $16.90 | 2021 | |
| Braintree Laboratories, INC. | $14.23 | 2020 | |
| Baxter Healthcare | $12.67 | 2022 | |
| Organon LLC | $9.66 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Scheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.